Business
HeartBeam Reports Fourth Quarter and Full Year 2022 Financial Results
Acquired Assets from LIVMOR, Extending Reach in Remote Monitoring and Detection with an Existing Cutting Edge FDA-Cleared Product, Halo+™ Atrial Fibrillation
About this update from Heartbeam, Inc.
[{"type":"text","content":"\nAcquired Assets from LIVMOR, Extending Reach in Remote Monitoring and Detection with an Existing Cutting Edge FDA-Cleared Product, Halo+™ Atrial Fibrillation Detection System\n\nPartnered with Evolve Manufacturing to Build HeartBeam AIMIGo 12-Lead 3D Vector Electrocardiogram Device\n\nReceived European Patent for HeartBeam AIMIGo Technology\n\nInitial FDA Submission of HeartBeam AIMIGo™, the Telehealth Solution, Projected for Q2 2023\n\nManagement to Host Webcast and Conference Call Today At 4:30 p.m. ET\n\n SANTA CLARA, Calif.--(BUSINESS WIRE)--\nHeartBeam, Inc. (NASDAQ: BEAT), a cardiac technology company that has developed the first and only 3D vector electrocardiogram (VECG) platform for heart attack detection anytime, anywhere, has reported its financial and operational results for the fourth quarter and full year ended December 31, 2022.\n\nFourth Quarter and Subsequent 2023 Operational Highlights\n\n\nStrategic acquisition (the “Acquisition”) of substantially all assets from LIVMOR, a digital health solutions company providing a patient-engaging remote monitoring system of critical physiological biomarkers, including FDA-cleared Halo+™ Atrial Fibrillation Detection System and physician-prescribed Integrated Patient Care Platform deployed within the Dallas, TX VA Healthcare System\n\n\nAcquisition includes 3 issued United States patents, LIVMOR’s business contracts and relationships as well as all Samsung watch and tablet inventory\n\n\nPartnered with Evolve Manufacturing to build HeartBeam AIMIGo 12-Lead 3D vector electrocardiogram device, positioning HeartBeam AIMIGo for early market testing in Q4 2023 after anticipated FDA clearance\n\n\nGranted European patent for signal transformation from vector electrocardiogram to 12-Lead electrocardiogram, offering protection for HeartBeam’s flagship technology in multiple countries in Europe\n\n\nReceived new patent for 12-Lead electrocardiogram smartwatch-based monitor intended for detection of heart attacks and complex cardiac arrhythmias\n\n\nAppointed senior medical technology executive Robert Eno as President to enhance HeartBeam’s strategic operations and capabilities\n\n\nAnnounced Robert Eno will assume the duties and responsibilities of Executive Vice President and Chief Business Officer Jon Hunt, Ph.D., who stepped down from his position and transitioned to the role o...